Kura Oncology (NASDAQ:KURA) SVP Sells $48,373.50 in Stock

Posted by Stanley Muller on Oct 2nd, 2026

Kura Oncology, Inc. (NASDAQ:KURA – Get Free Report) SVP Thomas Doyle sold 4,607 shares of the company’s stock in a transaction on Monday, September 28th. The shares were sold at an average price of $10.50, for a total value of $48,373.50. Following the completion of the sale, the senior vice president owned 142,428 shares of the company’s stock, valued at approximately $1,495,494. The trade was a 3.13% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Kura Oncology Stock Down 0.6%

Shares of KURA opened at $10.65 on Friday. Kura Oncology, Inc. has a 52-week low of $7.36 and a 52-week high of $13.90. The company has a quick ratio of 4.71, a current ratio of 4.73 and a debt-to-equity ratio of 0.12. The stock has a fifty day simple moving average of $11.23 and a two-hundred day simple moving average of $10.19. The company has a market capitalization of $947.42 million, a PE ratio of -3.16 and a beta of 0.47.

Kura Oncology (NASDAQ:KURA – Get Free Report) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.77) earnings per share for the quarter, beating the consensus estimate of ($0.88) by $0.11. Kura Oncology had a negative net margin of 384.30% and a negative return on equity of 207.18%. The firm had revenue of $20.87 million for the quarter, compared to analysts’ expectations of $20.16 million. As a group, equities analysts forecast that Kura Oncology, Inc. will post -3.25 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of KURA. BlackRock Inc. acquired a new stake in shares of Kura Oncology during the second quarter valued at about $115,286,000. Armistice Capital LLC lifted its holdings in shares of Kura Oncology by 5.7% in the 4th quarter. Armistice Capital LLC now owns 4,936,000 shares of the company’s stock worth $51,285,000 after acquiring an additional 264,000 shares during the last quarter. Bank of America Corp DE purchased a new position in shares of Kura Oncology during the 2nd quarter worth approximately $12,735,000. Dimensional Fund Advisors LP boosted its position in shares of Kura Oncology by 32.3% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,425,945 shares of the company’s stock worth $11,591,000 after purchasing an additional 348,127 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of Kura Oncology during the 2nd quarter worth approximately $10,927,000.

Trending Headlines about Kura Oncology

Here are the key news stories impacting Kura Oncology this week:

Positive Sentiment: JPMorgan initiated coverage of Kura Oncology with an “overweight” rating and a $30 price target, implying substantial upside from recent trading levels. The firm views Kura as a promising precision-cancer-medicine developer, particularly because of its menin-inhibitor platform and lead program, ziftomenib, for genetically defined acute myeloid leukemia. JPMorgan Kura Oncology rating article
Positive Sentiment: CNBC highlighted JPMorgan’s view that KURA could nearly triple, reinforcing the potential valuation impact of successful clinical and regulatory execution. The bullish outlook is particularly important for a biotechnology stock trading below the average analyst target of approximately $25.40. CNBC Kura Oncology analyst outlook
Neutral Sentiment: Kura’s financial position remains relatively liquid, with a reported quick ratio of 4.71 and current ratio of 4.73, but the company remains unprofitable and analysts expect a significant full-year loss. That means the stock’s valuation continues to depend heavily on clinical progress rather than current earnings.
Negative Sentiment: Multiple insiders, including executives Kathleen Ford, Brian Powl, Mollie Leoni, Thomas Doyle and Teresa Bair, sold shares in late September and October 1. The reported transactions represent roughly 97,000 shares and more than $1 million in proceeds, creating a potential near-term overhang. The sales do not necessarily indicate deteriorating business prospects, since the insiders retained meaningful holdings, but they may weigh on investor confidence. Kura Oncology insider sales

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the stock. Morgan Stanley set a $24.00 target price on shares of Kura Oncology in a report on Monday, August 24th. Citizens Jmp reaffirmed a “market outperform” rating and set a $24.00 price target on shares of Kura Oncology in a research report on Monday, August 24th. Wedbush upped their price objective on Kura Oncology from $36.00 to $38.00 and gave the company an “outperform” rating in a report on Thursday, August 13th. CLSA set a $24.00 price objective on Kura Oncology in a research report on Thursday, June 4th. Finally, Wells Fargo & Company set a $24.00 target price on Kura Oncology in a research note on Thursday, June 4th. Eleven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $25.69.

Get Our Latest Analysis on Kura Oncology

About Kura Oncology

(Get Free Report)

Kura Oncology, Inc is a biopharmaceutical company focused on developing precision medicines for the treatment of cancer. The company’s research programs target specific genetic and molecular abnormalities that contribute to tumor growth, with an emphasis on hematologic malignancies and selected solid tumors.

Kura’s leading program has been ziftomenib, an oral, selective menin inhibitor being developed for genetically defined forms of acute myeloid leukemia, including cancers with NPM1 mutations or certain KMT2A rearrangements.